Lung cancer key for Takeda's alisertib after Ph III lymphoma flop
This article was originally published in Scrip
Executive Summary
Takeda's hopes for its first-in-class Aurora kinase inhibitor now rest on Phase II studies in lung cancer after the company pulled the plug on its Phase III trial in a rare form of lymphoma.
You may also be interested in...
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
CureVac’s German Owner Rejects US Coronavirus Vaccine Grab
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Need a specific report? 1000+ reports available
Buy Reports